Tests CT103A, a BCMA CAR-T cell treatment, in newly diagnosed high-risk multiple myeloma

Trial details

Who runs it

Nanjing IASO Biotechnology Co., Ltd.

Trial code

NCT05181501

Record updated

6 January 2022

Original description

This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.Read full original descriptionShow less

A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)

This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.

Inclusion: 18 to 70 years old, male or female; Newly diagnosed as high-risk multiple myeloma:; Revised Multiple Myeloma International Staging System (R-ISS) stage 3; Double-hit or triple-hit according to FISH test; Presence of measurable lesions during screening according to any of the following criteria:; The proportion of primitive naive or monoclonal plasma cells ≥ 5% by bone marrow cytology, bone marrow biopsy histology or flow cytometry; Serum monoclonal protein (M-protein) level: M protein ≥10 g/L for IgG type, M protein ≥5g/L for IgA, IgD, IgM, and IgE type; Urine M protein level ≥200 mg/24 hours; Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio; ECOG score of 0 or 1; Expected survival time ≥ 12 weeks; Subjects must have appropriate organ functions and meet all the following laboratory test requirements before enrollment:; Hematology: Absolute neutrophil count (ANC) ≥ 1×10\^9/L (prior growth factor support is allowed, but supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10\^9/L; platelets≥75×10\^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test; recombinant human erythropoietin is allowed); Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN; Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min; Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN; Blood oxygen saturation>91%; Left ventricular ejection fraction (LVEF) ≥50%; Subjects and their spouses agree to take effective tools or contraceptive measures (safe period contraception is not included) from the time the subject signs the informed consent form until one year after the CAR-T cell infusion.

Exclusion: Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia; Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment; Patient with hypertension that cannot be controlled by medication; Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases that require drug treatment; Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast; Patient with a history of solid organ transplantation; Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive; Patient with mental illness or disturbance of consciousness or central nervous system disease; Patient who needs chronic use of immunosuppressive agents; Patient who is suspected with or with symptoms of central nervous system invasion by plasma cell tumors; Multiple myeloma patients with plasma cell leukemia; Women who are pregnant or breastfeeding; Other situations considered unsuitable by the investigator.

ClinicalTrials.gov NCT05181501